Josefine Bertz

922 total citations
15 papers, 493 citations indexed

About

Josefine Bertz is a scholar working on Molecular Biology, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Josefine Bertz has authored 15 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Physiology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Josefine Bertz's work include Alzheimer's disease research and treatments (6 papers), Neuroscience and Neuropharmacology Research (4 papers) and Connective Tissue Growth Factor Research (2 papers). Josefine Bertz is often cited by papers focused on Alzheimer's disease research and treatments (6 papers), Neuroscience and Neuropharmacology Research (4 papers) and Connective Tissue Growth Factor Research (2 papers). Josefine Bertz collaborates with scholars based in Australia, Switzerland and United Kingdom. Josefine Bertz's co-authors include Lars M. Ittner, Arne Ittner, Matthias Arlt, Walter Born, Bruno Fuchs, Roman Muff, Yazi D. Ke, Kristie Stefanoska, Alexander Volkerling and Amadeus Gladbach and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Neuroscience and Scientific Reports.

In The Last Decade

Josefine Bertz

15 papers receiving 488 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Josefine Bertz Australia 14 271 182 131 69 64 15 493
Damian Brockschnieder Germany 12 246 0.9× 127 0.7× 150 1.1× 83 1.2× 39 0.6× 15 738
Georgia Minakaki Germany 11 260 1.0× 201 1.1× 189 1.4× 81 1.2× 101 1.6× 13 710
Taehwan Shin United States 7 524 1.9× 202 1.1× 108 0.8× 56 0.8× 83 1.3× 7 710
An Verheyen Belgium 8 272 1.0× 213 1.2× 168 1.3× 82 1.2× 44 0.7× 8 513
April M. Weissmiller United States 16 584 2.2× 213 1.2× 174 1.3× 41 0.6× 131 2.0× 30 926
Meike Hick Germany 11 235 0.9× 375 2.1× 211 1.6× 54 0.8× 85 1.3× 14 565
Magdalena A. Petryniak United States 8 416 1.5× 168 0.9× 184 1.4× 71 1.0× 76 1.2× 8 683
M. Catarina Silva United States 11 579 2.1× 234 1.3× 129 1.0× 66 1.0× 70 1.1× 12 825
Diogo Trigo Portugal 13 344 1.3× 141 0.8× 231 1.8× 112 1.6× 37 0.6× 18 654
Elisa Matas-Rico Netherlands 12 559 2.1× 110 0.6× 74 0.6× 45 0.7× 177 2.8× 19 744

Countries citing papers authored by Josefine Bertz

Since Specialization
Citations

This map shows the geographic impact of Josefine Bertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josefine Bertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josefine Bertz more than expected).

Fields of papers citing papers by Josefine Bertz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josefine Bertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josefine Bertz. The network helps show where Josefine Bertz may publish in the future.

Co-authorship network of co-authors of Josefine Bertz

This figure shows the co-authorship network connecting the top 25 collaborators of Josefine Bertz. A scholar is included among the top collaborators of Josefine Bertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josefine Bertz. Josefine Bertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ittner, Arne, Prita R. Asih, Josefine Bertz, et al.. (2020). Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ. Acta Neuropathologica. 140(3). 279–294. 26 indexed citations
2.
Teo, Jonathan D., Holly P. McEwen, Jun Yup Lee, et al.. (2019). Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience. 39(48). 9645–9659. 23 indexed citations
3.
Ittner, Arne, et al.. (2018). Generation of a New Tau Knockout (tauΔex1) Line Using CRISPR/Cas9 Genome Editing in Mice. Journal of Alzheimer s Disease. 62(2). 571–578. 30 indexed citations
4.
Stefanoska, Kristie, Josefine Bertz, Alexander Volkerling, et al.. (2018). Neuronal MAP kinase p38α inhibits c-Jun N-terminal kinase to modulate anxiety-related behaviour. Scientific Reports. 8(1). 14296–14296. 29 indexed citations
5.
Stefanoska, Kristie, Alexander Volkerling, Josefine Bertz, et al.. (2018). An N-terminal motif unique to primate tau enables differential protein–protein interactions. Journal of Biological Chemistry. 293(10). 3710–3719. 50 indexed citations
6.
Martin, Adam D., Sook Wern Chua, Carol G. Au, et al.. (2018). Peptide Nanofiber Substrates for Long-Term Culturing of Primary Neurons. ACS Applied Materials & Interfaces. 10(30). 25127–25134. 15 indexed citations
7.
Boro, Aleksandar, Matthias Arlt, Bernhard Robl, et al.. (2015). Prognostic value and in vitro biological relevance of Neuropilin 1 and Neuropilin 2 in osteosarcoma. PubMed. 7(3). 640–53. 16 indexed citations
8.
Ittner, Arne, et al.. (2014). p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer’s disease. Acta Neuropathologica Communications. 2(1). 149–149. 62 indexed citations
9.
Ittner, Arne, et al.. (2014). The nucleotide exchange factor SIL1 is required for glucose-stimulated insulin secretion from mouse pancreatic beta cells in vivo. Diabetologia. 57(7). 1410–1419. 24 indexed citations
10.
Ittner, Arne, et al.. (2014). Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice. Journal of Neurochemistry. 132(1). 135–145. 62 indexed citations
11.
Arlt, Matthias, Roman Muff, Knut Husmann, et al.. (2013). Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1832(8). 1173–1182. 40 indexed citations
12.
Arlt, Matthias, In go J. Banke, Josefine Bertz, et al.. (2013). Reduced Latency in the Metastatic Niche Contributes to the More Aggressive Phenotype of LM8 Compared to Dunn Osteosarcoma Cells. Sarcoma. 2013. 1–13. 5 indexed citations
13.
Husmann, Knut, Matthias Arlt, Roman Muff, et al.. (2012). Matrix Metalloproteinase 1 promotes tumor formation and lung metastasis in an intratibial injection osteosarcoma mouse model. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1832(2). 347–354. 40 indexed citations
14.
Arlt, Matthias, Denise K. Walters, In go J. Banke, et al.. (2011). The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. International Journal of Cancer. 131(5). E804–12. 16 indexed citations
15.
Arlt, Matthias, Roman Muff, Beata Bode, et al.. (2011). Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. Journal of Bone and Mineral Research. 27(1). 58–67. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026